Discovery of the RANKL/RANK/OPG system

Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss

(2018) Jinhu Xiong et al.   Nature Communications

Coupling of bone resorption and formation by RANKL reverse signalling

(2018) Yuki Ikebuchi et al.   NATURE

Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy

(2018) Elizabeth Ahern et al.   Nature Reviews Clinical Oncology

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer

(2017) Shuan Rao et al.   GENES & DEVELOPMENT

Local administration of WP9QY (W9) peptide promotes bone formation in a rat femur delayed-union model

(2017) Mikiya Sawa et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases

(2017) Hibiki Udagawa et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis

(2017) Yuki Ozaki et al.   PLoS One

Peptide drugs accelerate BMP-2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling

(2016) Yasutaka Sugamori et al.   BIOESSAYS

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma

(2016) Mark J. Smyth et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance

(2014) Imran S. Khan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

(2013) Yuriko Furuya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

(2012) Giorgio Vittorio Scagliotti et al.   Journal of Thoracic Oncology

Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor-κB Ligand-neutralizing Antibody

(2011) Yuriko Furuya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling

(2011) Wei Tan et al.   NATURE

Matrix-embedded cells control osteoclast formation

(2011) Jinhu Xiong et al.   NATURE MEDICINE

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

(2011) Tomoki Nakashima et al.   NATURE MEDICINE

Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector

(2010) Tetsuro Enomoto et al.   JOURNAL OF BONE AND MINERAL METABOLISM

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

(2010) Eva Gonzalez-Suarez et al.   NATURE

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

(2010) Daniel Schramek et al.   NATURE

Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss*

(2009) Yoshiya Tomimori et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Tumor Necrosis Factor Family Receptors RANK and CD40 Cooperatively Establish the Thymic Medullary Microenvironment and Self-Tolerance

(2008) Taishin Akiyama et al.   IMMUNITY